Page last updated: 2024-11-04

vorinostat and Aggressive Natural Killer Cell Leukemia

vorinostat has been researched along with Aggressive Natural Killer Cell Leukemia in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sun, X1
Hasanali, ZS1
Chen, A1
Zhang, D1
Liu, X1
Wang, HG1
Feith, DJ1
Loughran, TP1
Xu, K1

Other Studies

1 other study available for vorinostat and Aggressive Natural Killer Cell Leukemia

ArticleYear
Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
    British journal of haematology, 2015, Volume: 168, Issue:3

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Dose-Response Re

2015